This study is the second cross-sectional study conducted in the region. In the first cross sectional study, conducted in the winter of 2020, we aimed to estimate the seroprevalence of SARS-CoV-2 IgG antibodies among blood donors in Sarajevo Canton. We also assessed immune durability among seropositive participants after 6 months. In total, of 1015 blood donors aged 18-65 years in Sarajevo Canton between 2 November and 3 December 2020 were recruited and population-weighted seroprevalence in Sarajevo Canton was 19.2% (95% CI: 16.7-21.6%). The aim of this second cross-sectional study is to measure the seroprevalence SARS-CoV-2 antibodies and assess antibody kinetics in the blood donor population after 12 months.
Study Type
OBSERVATIONAL
Enrollment
1,152
Institute for Transfusion Medicine of the Federation of Bosnia and Herzegovina
Sarajevo, Bosnia and Herzegovina
Seroprevalence of SARS-CoV-2 IgG antibodies
Crude seroprevalence among blood donors will be adjusted to age and sex distribution in cantonal population and to test sensitivity and specificity using Bayesian statistical modeling.
Time frame: November 2021-December 2021
Assess factors associated with seropositivity.
Chi-squared test will be conducted on categorical variables.
Time frame: November 2021-December 2021
Assess antibody response across types of immunity.
Among those with positive anti-S antibodies, geometric mean titers will be compared across participants with natural immunity, vaccine-induced immunity, and hybrid of natural and vaccine-induced immunity.
Time frame: November 2021-December 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.